Galectin Therapeutics (GALT) Return on Capital Employed Growth (3y) (2014 - 2026)
Galectin Therapeutics (GALT) Return on Capital Employed Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,071.19 Bn | 1,071.19 Bn | - | - |
| 4 | BeOne Medicines | 469.11 Bn | 464.32 Bn | 1.35 Bn | 4,893.00 |
| 5 | Vertex Pharmaceuticals | 123.03 Bn | 115.78 Bn | 2.59 Bn | -494.00 |
| 6 | Regeneron Pharmaceuticals | 70.13 Bn | 61.37 Bn | 3.31 Bn | -649.00 |
| 7 | Belite Bio | 63.44 Bn | 63.44 Bn | - | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 4,853.00 |
| 10 | Galectin Therapeutics | 223.00 Mn | 223.00 Mn | - | 26,296.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26,296.00 |
| Dec 31, 2025 | 33,631.00 |
| Sep 30, 2025 | 30,930.00 |
| Jun 30, 2025 | -171,227.00 |
| Mar 31, 2025 | 16,171.00 |
| Dec 31, 2024 | 44,618.00 |
| Sep 30, 2024 | -118,337.00 |
| Jun 30, 2024 | -19,839.00 |
| Mar 31, 2024 | -13,808.00 |
| Dec 31, 2023 | -31,181.00 |
| Sep 30, 2023 | -31,018.00 |
| Jun 30, 2023 | -32,739.00 |
| Mar 31, 2023 | -38,770.00 |
| Dec 31, 2022 | -55,348.00 |
| Sep 30, 2022 | -26,327.00 |
| Jun 30, 2022 | -14,903.00 |
| Mar 31, 2022 | 3,708.00 |
| Dec 31, 2021 | 7,891.00 |
| Sep 30, 2021 | 2,864.00 |
| Jun 30, 2021 | 9,397.00 |